Aadi Bioscience, Inc. (NASDAQ:AADI – Get Free Report) traded down 1.7% during mid-day trading on Thursday . The stock traded as low as $4.04 and last traded at $4.07. Approximately 599,377 shares changed hands during mid-day trading, an increase of 130% from the average daily volume of 261,100 shares. The stock had previously closed at $4.14.
Aadi Bioscience Stock Performance
The stock has a market capitalization of $117.56 million, a price-to-earnings ratio of -2.09 and a beta of 0.68. The company has a 50 day moving average of $4.11 and a 200 day moving average of $3.76.
About Aadi Bioscience
Aadi Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for genomically defined cancers. Headquartered in Redwood City, California, Aadi Bioscience was founded in 2012 and went public in 2019 on the Nasdaq Stock Market under the ticker AADI. The company’s research strategy centers on identifying molecular drivers of tumor growth and designing small-molecule inhibitors that target these pathways.
The company’s lead product candidate, fimepinostat (CUDC-907), is a novel dual inhibitor of histone deacetylase (HDAC) and phosphatidylinositol 3-kinase (PI3K).
Recommended Stories
- Five stocks we like better than Aadi Bioscience
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
- Why These 3 Equal Weight ETFs Have Outperformed the S&P This Year
Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
